Please try another search
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Name | Age | Since | Title |
---|---|---|---|
Chaim Hurvitz | 61 | - | Director |
Yafit Stark | 69 | 2008 | Clinical Development Strategy Advisor |
Yechezkel Barenholz | 83 | 2008 | Independent Director |
Moshe Salai | - | - | Member of Scientific Advisory Board |
Erez Kachel | - | - | Member of Scientific Advisory Board |
Hartzell V. Schaff | - | 2017 | Member of Scientific Advisory Board |
Robert Benjamin Stein | 73 | 2020 | Independent Director |
Dikla Czaczkes Akselbrad | 51 | 2014 | CEO & Director |
Itzhak Krinsky | 71 | 2019 | Independent Director |
Jacob Harel | 69 | 2017 | Independent Chairman |
Mitchel S. Berger | - | 2022 | Member of Scientific Advisory Board |
Joseph BenAmram | 60 | 2023 | Independent Director |
Nir Dror | 48 | 2020 | Independent Director |
Frederick Lang | - | 2021 | Member of Scientific Advisory Board |
Nurit Tweezer-Zaks | 58 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review